{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:54:32Z","timestamp":1790351672538,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372309"],"award-info":[{"award-number":["82372309"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Evidence Based Medicine"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Carbapenem\u2010resistant hypervirulent\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      (CR\u2010hvKp) is a growing concern due to high mortality and limited therapies, with scarce data on novel antimicrobials in vitro activity against it.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This research evaluated the in vitro efficacy of six novel antimicrobial drugs including ceftolozane\/tazobactam, cefiderocol, eravacycline, omadacycline, temocillin, and plazomicin, against CR\u2010hvKP and characterize its molecular epidemiology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      106 non\u2010repetitive clinical CR\u2010hvKP strains were collected from Sichuan Provincial People's Hospital between August 2018 and December 2023. CR\u2010hvKP were identified using VITEK\u20102 Compact and MALDI\u2010TOF MS, confirmed via string tests and PCR. The E\u2010test strip method assessed the in vitro antibacterial activity of novel antimicrobial drugs against CR\u2010hvKP. The molecular characterization of CR\u2010hvKP was conducted by PCR to amplify resistance genes, virulence genes, housekeeping genes, and\n                      <jats:italic>wzi<\/jats:italic>\n                      genes. The\n                      <jats:italic>Galleria mellonella<\/jats:italic>\n                      infection model explored the virulence characteristics of CR\u2010hvKP strains.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CR\u2010hvKP had a relatively high susceptibility rate of 96.2% to cefiderocol, showing good antibacterial activity, whereas ceftolozane\/tazobactam, temocillin, omadacycline, eravacycline, and plazomicin exhibited high resistance rates (81.1%\u201399.1%). ST11\u2010KL64 was the predominant type in CR\u2010hvKP strains. We identified three new ST subtypes, ST8115, ST8116 and ST8117. The most prevalent carbapenemase genes were\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>KPC<\/jats:sub>\n                      and\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>NDM<\/jats:sub>\n                      , and approximately 75.5% of CR\u2010hvKP carried\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>KPC<\/jats:sub>\n                      ,\n                      <jats:italic>bla<\/jats:italic>\n                      <jats:sub>SHV<\/jats:sub>\n                      , and\n                      <jats:italic>bl<\/jats:italic>\n                      a\n                      <jats:sub>CTX\u2010M<\/jats:sub>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cefiderocol appears highly promising as a therapy for CR\u2010hvKP infections. Our findings will not only effectively address the challenge of CR\u2010hvKP resistance, but also provide evidence to support the optimization of clinical therapeutic strategies and further promote the development and application of novel antimicrobial drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jebm.70113","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T02:57:21Z","timestamp":1769741841000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Susceptibility Studies of Novel Antimicrobial Drugs Against Carbapenem\u2010Resistant and Hypervirulent\n                    <i>Klebsiella pneumoniae<\/i>"],"prefix":"10.1111","volume":"19","author":[{"given":"Yi","family":"Li","sequence":"first","affiliation":[{"name":"School of Medicine University of Electronic Science and Technology of China  Chengdu China"},{"name":"Department of Laboratory Medicine Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Medicine University of Electronic Science and Technology of China  Chengdu China"},{"name":"Department of Laboratory Medicine Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine The Affiliated Hospital of Southwest Medical University  Luzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Jia","sequence":"additional","affiliation":[{"name":"School of Medicine University of Electronic Science and Technology of China  Chengdu China"},{"name":"Department of Laboratory Medicine Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huinan","family":"Mao","sequence":"additional","affiliation":[{"name":"College of Medical Technology Chengdu University of Traditional Chinese Medicine  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Qionglai Medical Center Hospital  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China  Chengdu China"},{"name":"Sichuan Provincial Key Laboratory for Human Disease Gene Study Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2020.08.002"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0315-1"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2018.00004"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2014.09.003"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-90414-4"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00001-19"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.09.004"},{"key":"e_1_2_8_9_1","unstructured":"WHO.WHO Updates List of Drug\u2010Resistant Bacteria Most Threatening to Human Health [Internet] [cited 2025 May 23] https:\/\/www.who.int\/news\/item\/17\u201005\u20102024\u2010who\u2010updates\u2010list\u2010of\u2010drug\u2010resistant\u2010bacteria\u2010most\u2010threatening\u2010to\u2010human\u2010health."},{"key":"e_1_2_8_10_1","unstructured":"CDC.Antimicrobial Resistance.2025. 2019 antibiotic resistance threats report. [cited 2025 May 23] https:\/\/www.cdc.gov\/antimicrobial\u2010resistance\/data\u2010research\/threats\/index.html."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2103454"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2023.09.040"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2049458"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1060050"},{"key":"e_1_2_8_15_1","volume-title":"Tigecycline\u2014Injection Products","author":"Center for Drug Evaluation and Research (CDER)","year":"2023"},{"key":"e_1_2_8_16_1","volume-title":"Omadacycline Injection and Oral Products","author":"Center for Drug Evaluation and Research (CDER)","year":"2022"},{"key":"e_1_2_8_17_1","unstructured":"EUCAST.Clinical Breakpoint Tables [Internet]. [cited 2025 May 20] https:\/\/www.eucast.org\/bacteria\/clinical\u2010breakpoints\u2010and\u2010interpretation\/clinical\u2010breakpoint\u2010tables\/."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01924-13"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02806-23"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)62567-6"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1986.00360220057011"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-024-00686-3"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00936-5"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2020.04.012"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2023.10.038"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-024-02016-0"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12040761"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00290-09"},{"key":"e_1_2_8_29_1","article-title":"Comparative Iin Vitro Activity of Piperacillin\u2010Tazobactam and Temocillin against Third\u2010Generation Cephalosporin\u2010Resistant, Carbapenem\u2010Susceptible Escherichia coli and kKebsiella pneumoniae","volume":"9","author":"Kresken M.","year":"2021","journal-title":"GMS Infectious Diseases"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw066"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-020-03898-5"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00115-20"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx136"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59030518"},{"issue":"4","key":"e_1_2_8_35_1","first-page":"463","article-title":"Microbiological, Clinical, and PK\/PD Features of the New Anti\u2010Gram\u2010Negative Antibiotics: \u0392\u2010Lactam\/\u03b2\u2010Lactamase Inhibitors in Combination and Cefiderocol\u2014An All\u2010Inclusive Guide for Clinicians","volume":"15","author":"Principe L.","year":"2022","journal-title":"Pharma (Basel Switzerland)"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00286-6"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106377"},{"key":"e_1_2_8_38_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101038","article-title":"Dynamic Within\u2010Host Cefiderocol Heteroresistance Caused by blaSHV\u201012 Amplification in Pandrug\u2010Resistant and Hypervirulent Klebsiella pneumoniae Sequence Type 11","volume":"73","author":"Liu C.","year":"2024","journal-title":"Drug Resist Updates: Rev Comment Antimicrob Anticancer Chemother"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03223-23"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02351-23"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz395"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2022.115651"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-020-03877-w"},{"issue":"12","key":"e_1_2_8_44_1","article-title":"Discordant Susceptibilities of Enterobacterales to Different Tetracycline Classes","volume":"16","author":"Flores H.","year":"2024","journal-title":"Cureus"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz640"},{"issue":"1","key":"e_1_2_8_46_1","first-page":"81","article-title":"In Vitro Antimicrobial Activity of Five Newly Approved Antibiotics Against Carbapenemase\u2010Producing Enterobacteria\u2014A Pilot Study in Bulgaria","volume":"13","author":"Markovska R.","year":"2024","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1390966"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.03.023"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-024-03564-2"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2022.105593"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1325077"}],"container-title":["Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jebm.70113","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jebm.70113","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jebm.70113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:13:33Z","timestamp":1783023213000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jebm.70113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/jebm.70113"],"URL":"https:\/\/doi.org\/10.1111\/jebm.70113","archive":["Portico"],"relation":{},"ISSN":["1756-5383","1756-5391"],"issn-type":[{"value":"1756-5383","type":"print"},{"value":"1756-5391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"2025-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70113"}}